Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering MyelomaDickran Kazandjian, Ola Landgren, Min-Jung Lee et al.|JAMA Oncology|2021Cited by 46
Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple MyelomaDickran Kazandjian, Jennifer Jones, Alexander Dew et al.|The Oncologist|2021Cited by 26
Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative StudyDickran Kazandjian, Ola Landgren, Elizabeth Hill et al.|Blood|2020Cited by 10
Fixed Duration Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Maintenance Leads to High Rates of Sustained MRD Negativity in Patients with High-Risk Smoldering Multiple Myeloma: Long Term Follow up of an Investigator Initiated Phase 2 TrialElizabeth Hill, Dickran Kazandjian, Joseph Roswarski et al.|Blood|2023Cited by 6
A Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple MyelomaRoshani Patel, Elizabeth Hill, Amrit Bhaskarla et al.|Blood|2024Cited by 0